-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The induction of protective immunity after SARS-CoV-2 infection and/or vaccination is essential to suppress transmission.
The induction of protective immunity after SARS-CoV-2 infection and/or vaccination is essential to suppress transmission.
The researchers compared IBD patients treated with infliximab with patients treated with vedolizumab, and explored the relationship between patients' reduced response to vaccines or increased sensitivity to systemic infections.
Patients using two different biological agents had similar symptoms and confirmed SARS-CoV-2 infection rates between the two groups.
Therefore, this study finally confirmed that infliximab is related to the weakened serological response to the new coronavirus (SARS-CoV-2), and immunomodulators as concomitant therapy further weakened this response.
Therefore, this study finally confirmed that infliximab is related to the weakened serological response to the new coronavirus (SARS-CoV-2), and immunomodulators as concomitant therapy further weakened this response.
Original source:
Nicholas A Kennedy.
bmj.
com/content/early/2021/03/19/gutjnl-2021-324388" target="_blank" rel="noopener">Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.
Leave a message here